Venetoclax, CLAD/LDAC and azacitdine in older AML patients

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023Подробнее

Venetoclax and azacitidine in older patients with AMLПодробнее

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AMLПодробнее

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 yearsПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

The role of venetoclax in older patients with AMLПодробнее

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Venetoclax and azacitidine for AML ineligible for standard inductionПодробнее

Venetoclax + azacitidine in unfit patients with AMLПодробнее

Venetoclax and azacitidine for young patients with AMLПодробнее

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”Подробнее

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AMLПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

Venetoclax plus azacitidine for higher-risk MDSПодробнее

AML: Optimizing Selection and Use of Venetoclax + AzacitidineПодробнее

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AMLПодробнее

Treating older patients with AML in 2020: What is new and promising?Подробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее